Share on StockTwits

Research analysts at B. Riley increased their price objective on shares of McKesson Corp. (NYSE:MCK) to $190.00 in a report released on Monday, reports. The firm currently has a “neutral” rating on the stock. B. Riley’s price objective suggests a potential upside of 13.01% from the company’s current price.

McKesson Corp. (NYSE:MCK) opened at 168.12 on Monday. McKesson Corp. has a one year low of $101.46 and a one year high of $177.00. The stock’s 50-day moving average is $162.8 and its 200-day moving average is $140.6. The company has a market cap of $38.619 billion and a P/E ratio of 28.65.

McKesson Corp. (NYSE:MCK) last announced its earnings results on Thursday, October 24th. The company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.24. The company had revenue of $33.00 billion for the quarter, compared to the consensus estimate of $32.16 billion. During the same quarter in the previous year, the company posted $1.92 earnings per share. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. Analysts expect that McKesson Corp. will post $8.61 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on MCK. Analysts at Raymond James upgraded shares of McKesson Corp. from an “outperform” rating to a “strong-buy” rating in a research note to investors on Monday, January 6th. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of McKesson Corp. in a research note to investors on Thursday, December 26th. They now have a $181.00 price target on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of McKesson Corp. in a research note to investors on Friday, November 29th. They now have a $199.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $165.00.

McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.